Information  X 
Enter a valid email address

Lipoxen PLC (XEN)

  Print      Mail a friend

Wednesday 30 September, 2009

Lipoxen PLC

Senior Management Appointment

RNS Number : 8938Z
Lipoxen PLC
30 September 2009
 



For immediate release


30 September 2009

Lipoxen plc

('Lipoxen' or 'the Company')

Appointment of Director of Project Management 


Lipoxen plc (AIM: LPX), a bio-pharmaceutical company specialising in the development of high-value differentiated biologicals, vaccines and siRNA delivery, is pleased to announce the appointment of Dr David Moss as Director of Project ManagementDr Moss's appointment builds on Lipoxen's announcement today that it has been appointed the lead member of the grant consortium for its controlled-release nanoparticle vaccine programme by the Technology Strategy Board, the Government organisation charged with driving UK innovation.


Dr Moss joined the Company in early September and is charged not only with advancing the Technology Strategy Board programme in particular (given his substantial experience and track record in developing innovative vaccine formulations), but also with both strengthening the Lipoxen management team at the operating level and furthering the Company's Business Development efforts, especially but not exclusively, the initiation of new vaccine and siRNA projects.


Dr Moss has almost thirty years of research, development and project management experience gained from roles in both academia and the private biotech sector. His focus during this period has been on the development of vaccines for veterinary and human applications. He joins Lipoxen from Cambridge Biostability Ltd (CBL) where he was Director of Research and was responsible for the company's entire research programme focused on the development of thermostable vaccines and biopharmaceuticals. This included the Technology Strategy Board-funded vaccine programme. Prior to CBL, he was Project Manager at Intervet UK (now Intervet Schering-Plough), a global veterinary vaccine and research and development company.


Commenting on Dr Moss's appointment, M. Scott Maguire, CEO of Lipoxen, said: 


'Dr Moss brings to Lipoxen both substantial commercial experience as well as exceptional vaccine development knowledge including, very pertinently, a deep familiarity with the Technology Strategy Board programme. Lipoxen's influenza vaccine development project is a key element of the Company's preclinical pipeline and it will be driven forward by Dr Moss as part of his overall scope of responsibilities which also includes top level project management of the burgeoning schedule of initiatives being undertaken by the Company. We welcome David Moss to the Lipoxen management team and wish him every possible success in his new role.'


- Ends -

For further information please contact:


Lipoxen plc

+44 (0)20 7389 5015 

M. Scott Maguire, Chief Executive Officer




Singer Capital Markets (nominated adviser)

+44 (0)20 3205 7500

Jeff Keating / Claes Spång 




Noble & Company

+44 (0) 20 7763 2200 

John Llewellyn-Lloyd / Sam Reynolds  




Buchanan Communications

+44 (0)20 7466 5000

Lisa Baderoon, Catherine Breen



Notes for Editors


About Lipoxen

Lipoxen plc is a biopharmaceutical company focused on the development of new and improved biologic drugs and vaccines. Lipoxen has three proprietary patented technology platforms:


1) PolyXen - for extending the efficacy and half life of biologic drugs

2) ImuXen - for creating new vaccines and improving existing vaccines

3) SiRNAblate - for the delivery of siRNA


Lipoxen's technology is designed to improve the efficacy, safety, stability, biological half-life and immunologic characteristics of its products.  


Lipoxen has multiple drug and vaccine programmes in development. Two products are in clinical development, SuliXen, a long acting insulin and ErepoXen, a long-acting erythropoietin (EPO). Lipoxen's preclinical pipeline includes vaccines against HIV, influenza and malaria and Factor VIII through an exclusive license with Baxter, the global healthcare company.


The Company has a low-risk business model and out-licenses its proprietary technologies to biopharmaceutical companies that have strong manufacturing and marketing capabilities. Lipoxen currently has commercial agreements with some of the world's leading biotechnology and pharmaceutical companies including Baxter, Schering-Plough, Sanofi-Aventis, the Serum Institute of India Limited, Genentech, Amgen and Genzyme. Furthermore, Baxter led the £2.9 million fundraising that the Company announced in May 2009, with a US$1 million investment.


Lipoxen, which was founded in 1997, now trades on the AIM Market of the London Stock Exchange under the ticker symbol LPX. More information can be found at the Company's website: www.lipoxen.com.



This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOALLMATMMITBPL